Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 169,445 |
|
|||||
| News | - | ||||||
| Day High | 3.20 | Low High |
|||||
| Day Low | 2.97 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| MDxHealth SA | MDXH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.17 | 5.72% | 3.14 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.10 | 2.97 | 3.20 | 3.14 | 2.97 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 532 | 169,445 | US$ 3.09 | US$ 523,855 | - | 2.15 - 4.64 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:13:29 | 2 | US$ 3.23 | USD |
MDxHealth SA Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 85.68M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MDxHealth News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MDXH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.46 | 3.20 | 2.45 | 2.78 | 44,914 | 0.68 | 27.64% |
| 1 Month | 2.72 | 3.20 | 2.21 | 2.49 | 49,389 | 0.42 | 15.44% |
| 3 Months | 3.46 | 3.85 | 2.21 | 2.86 | 71,761 | -0.32 | -9.25% |
| 6 Months | 2.90 | 4.64 | 2.21 | 3.29 | 67,347 | 0.24 | 8.28% |
| 1 Year | 3.65 | 4.64 | 2.15 | 3.43 | 89,461 | -0.51 | -13.97% |
| 3 Years | 12.15 | 13.17 | 2.15 | 4.30 | 76,295 | -9.01 | -74.16% |
| 5 Years | 12.15 | 13.17 | 2.15 | 4.30 | 76,295 | -9.01 | -74.16% |
MDxHealth Description
| MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe. |
